Yayın:
Profound on-treatment viral suppression with peginterferon alfa-2a (40KD) (PEGASYS (R)) plus lamivudine combination therapy limits the development of YMDD mutations, but does not improve sustained response rates over peginterferon alfa-2a (40KD) alone

Basit Görünüm
dc.contributor.authorGermanidis, G.
dc.contributor.authorMarcellin, P.
dc.contributor.authorLau, G.
dc.contributor.authorBonino, F.
dc.contributor.authorFarci, P.
dc.contributor.authorHadziyannis, S.
dc.contributor.authorJin, R.
dc.contributor.authorYao, G.B.
dc.contributor.authorPiratvisuth, T.
dc.contributor.authorYurdaydın, C.
dc.contributor.authorDiago, M.
dc.contributor.authorLai, M.Y.
dc.contributor.authorPopescu, M.
dc.contributor.authorPluck, N.
dc.contributor.buuauthorGürel, S.
dc.contributor.departmentTıp Fakültesi
dc.date.accessioned2022-11-17T07:07:08Z
dc.date.available2022-11-17T07:07:08Z
dc.date.issued2004-10
dc.descriptionBu çalışma, 29 Ekim-02 Kasım 2004 tarihleri arasında Boston[Amerika Birleşik Devletleri]’da düzenlenen 55. Annual Meeting of the American- Association for the Study of Liver Diseases (AASLD)’de bildiri olarak sunulmuştur.
dc.description.sponsorshipAmer Assoc Study Liver Dis
dc.identifier.citationGermanidis, G. vd. (2004). “Profound on-treatment viral suppression with peginterferon alfa-2a (40KD) (PEGASYS (R)) plus lamivudine combination therapy limits the development of YMDD mutations, but does not improve sustained response rates over peginterferon alfa-2a (40KD) alone”. Hepatology, 40(4), Supplement 1, 653A-653A.
dc.identifier.endpage653A
dc.identifier.issn0270-9139
dc.identifier.issue4, Supplement 1
dc.identifier.startpage653A
dc.identifier.urihttp://hdl.handle.net/11452/29471
dc.identifier.volume40
dc.identifier.wos000224102101133
dc.indexed.wosSCIE
dc.indexed.wosCPCIS
dc.language.isoen
dc.publisherWiley
dc.relation.collaborationYurt içi
dc.relation.collaborationYurt dışı
dc.relation.journalHepatology
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectGastroenterology and hepatology
dc.subject.wosGastroenterology and hepatology
dc.titleProfound on-treatment viral suppression with peginterferon alfa-2a (40KD) (PEGASYS (R)) plus lamivudine combination therapy limits the development of YMDD mutations, but does not improve sustained response rates over peginterferon alfa-2a (40KD) alone
dc.typeOther
dc.type.subtypeMeeting Abstract
dc.wos.quartileQ1
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi
local.indexed.atWOS

Dosyalar

Lisanslı seri

Şimdi gösteriliyor 1 - 1 / 1
Placeholder
Ad:
license.txt
Boyut:
1.71 KB
Format:
Item-specific license agreed upon to submission
Açıklama
İndir

Koleksiyonlar

İndeksli Yayınlar / Indexed Publications